|
IQVIA™ Real-World Insights Bibliography
| Direct-to-Patient Research: Piloting a New Approach to Understanding Drug Safety During Pregnancy. |
| Author(s): Dreyer NA1, Blackburn SC2, Mt-Isa S3, Richardson JL4, Thomas S4, Laursen M5, Zetstra-van der Woude P6, Jamry-Dziurla A7, Hliva V8, Bourke A9, de Jong-van den Berg L6. |
| Affiliations(s): 1Quintiles Real-World & Late Phase Research Cambridge, MA United States.
2Quintiles Real-World & Late Phase Research Reading United Kingdom.
3Imperial College London United Kingdom.
4Institute of Cellular MedicineNewcastle UniversityNewcastle upon TyneUnited Kingdom; UK Teratology Information ServiceNewcastle HospitalsNHS Foundation TrustNewcastle upon TyneUnited Kingdom.
5Statens Serum Institut Copenhagen Denmark.
6University of Groningen Groningen Netherlands.
7Poznan University of Medical Sciences Poznan Poland.
8Quintiles Real-World & Late-Phase Research St. Prex Switzerland.
9IMS London United Kingdom. |
Publication(s): JMIR Public Health Surveill. 2015 Dec 22;1(2):e22.
|
| Document Type(s): Article, |
| Countries: Denmark, Netherlands, Poland, UK, |
C:
Y: |
Drug safety, Womens Health,
2015 |
|
L:
A: |
English
direct-to-patient research, |
|
 |
| |
| |
| Cost-effectiveness of insulin aspart versus human soluble insulin in type 2 diabetes in four European countries: subgroup analyses from the PREDICTIVE study. |
| Author(s): Palmer JL1, Goodall G1, Nielsen S3, Kotchie RW,2 Valentine WJ1, Palmer AJ1, Roze S1. |
| Affiliations(s): 1IMS Health, Basel, Switzerland, 2Novo Nordisk, Bagsværd, Denmark, 3IMS Health, London, UK |
Publication(s): Curr Med Res Opin. 2008; 24(5):1417-1428
|
| Document Type(s): Manuscript in preparation, |
| Countries: Italy, Poland, Spain, Sweden, |
C:
Y: |
Diabetes,
2008 |
|
L:
A: |
English
Cost effectiveness, |
|
|
| |
| |
| Mealtime insulin aspart reduces the long-term cost of complications compared to human insulin as part of basal-bolus therapy in Polish type 2 diabetes patients |
| Author(s): Goodall G1, Nielsen S2, Townsend C2, Kotchie R3, Erny-Albrecht K1, Valentine WJ1 |
| Affiliations(s): 1 IMS Health, Basel, Switzerland; 2 NovoNordisk, Bagsværd, Denmark; 3 IMS Health, London, UK. |
Publication(s): ISPOR 2007 10th Annual European Congress, Dublin, Ireland, 20-23 October 2007
|
| Document Type(s): Poster, |
| Countries: Poland, |
C:
Y: |
Diabetes,
2007 |
|
L:
A: |
English
Cost effectiveness, |
|
|
| |
| |
| Cost-Effectiveness Of Biphasic Insulin Aspart 30 Versus Human Premix Insulin For Type 2 Diabetes Patients In A Polish Setting |
| Author(s): Aristides M1, Kotchie RW1, Nielsen S2, Townsend C2, Valentine WJ3, Scheijbeler HW1 |
| Affiliations(s): 1 IMS Health, London, UK; 2 Novo Nordisk A/S, Bagsværd, Denmark; 3 IMS Health, Basel, Switzerland |
Publication(s): ISPOR 2007 10th Annual European Congress
ISPOR 2007 10th Annual European Congress, Dublin, Ireland, 20 - 23 October 2007
|
| Document Type(s): Poster, |
| Countries: Poland, |
C:
Y: |
Diabetes,
2007 |
|
L:
A: |
English
Cost effectiveness, |
|
|
| |
| |
| Estimating the long-term clinical outcomes associated with switching to insulin aspart (novorapid®) from human soluble insulin in type 2 diabetes patients in the Polish setting |
| Author(s): Goodall G1, Valentine WJ1, Townsend C2, Kotchie RW3, Nielsen S2, Erny-Albrecht K1 |
| Affiliations(s): 1 IMS Health, Basel, Switzerland; 2 NovoNordisk, Bagsværd, Denmark; 3 IMS Health, London, UK. |
Publication(s): ISPOR 2007 10th Annual European Congress, Dublin, Ireland, 20-23 October 2007
|
| Document Type(s): Poster, |
| Countries: Poland, |
C:
Y: |
Diabetes,
2007 |
|
L:
A: |
English
Cost utility, |
|
|
| |
| |
 2 of 2
|
|
